Insulin Resistance Gene Discovery: New Opportunities Combining Human Genetics, Functional Genomics, and Bioinformatics
La Nouvelle Orleans Ballroom C
Level 2, Ernest N. Morial Convention Center
Q&A with Amit R. Majithia, MD
University of California, San Diego
What is your presentation about?
The presentation will focus on how new genomic and clinical technologies can be combined to identify insulin resistance genes that could form the basis of new therapies. The current state of genetic discovery in insulin resistance will be reviewed highlighting obstacles that have limited gene discovery so far. This will set the stage for a discussion of new approaches to overcome these obstacles and accelerate gene discovery by combining population scale human genetics, novel clinical measurements (e.g. CGM) and recently developed functional genomic techniques.
What makes this topic important in 2022?
We still have very few treatments that directly target insulin resistance but it continues to affect more and more people around the world causing type 2 diabetes, fatty liver disease and cardiovascular events. I believe this is an area that needs the focus of our scientific and clinical community
How did you become involved with this area of diabetes research or care?
My grandmother had diabetes. Seeing her live with it and, despite rigorous diet control, still suffer complications motivated me to pursue a career in diabetes research.
What are you most looking forward to at the 82nd Scientific Sessions?
After two years of pandemic closures, I am very much looking forward to reconnecting with scientific colleagues and friends!